David Reese, Amgen

Am­gen spot­lights pre­clin­i­cal 'mul­ti-specific­s' as an­a­lyst pre­dicts late-stage M&A

If David Reese gets his way, Lumakras will be the first of many Am­gen drugs that shat­ter the fences cur­rent­ly cor­don­ing off vast swaths of pro­tein tar­gets as “un­drug­gable.”

Lumakras, the ground­break­ing KRAS G12C in­hibitor 40 years in the mak­ing, did not dis­ap­point dur­ing its first months as a com­mer­cial drug — spurring sales of $36 mil­lion in a US launch that an­a­lysts said were “off to a strong start.” As Am­gen at­tempts to con­struct a whole pipeline around and read­ies a slate of next-gen KRAS can­di­dates, though, SVB Leerink an­a­lyst Ge­of­frey Porges warns it doesn’t have much time be­fore rev­enue ero­sion sits in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.